Drug Discovery and Development Industry: Lytix Biopharma AS – Product Pipeline Review – Q1 2011

• Publication date: June 2012
• Report size: 38 pages

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global In...

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Lytix Biopharma AS - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lytix Biopharma AS human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Lytix Biopharma AS with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Lytix Biopharma AS’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Lytix Biopharma AS’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of Lytix Biopharma AS in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Lytix Biopharma AS’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Lytix Biopharma AS.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Lytix Biopharma AS and identify potential opportunities in those areas.

Therapy Industry in Sweden

Table of Contents
Data table of Contents 2
List of Tables 3
List of Figures 3
Lytix Biopharma AS Snapshot 4
Lytix Biopharma AS Overview 4
Key Information 4
Key Facts 4
Lytix Biopharma AS – Research and Development Overview 5
Key Therapeutic Areas 5
Lytix Biopharma AS – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Pipeline Products – Combination Treatment Modalities 9
Lytix Biopharma AS – Pipeline Products Glance 10
Lytix Biopharma AS Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Lytix Biopharma AS–Early Stage Pipeline Products 12
Discovery Products/Combination Treatment Modalities 12
Lytix Biopharma AS – Drug Profiles 13
Lytixar 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
LTX-315 + GV1001 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Oncopore 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Kinase Modulators 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
LTX 200 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Lytix Biopharma AS – Pipeline Analysis 18
Lytix Biopharma AS – Pipeline Products by Therapeutic Class 18
Lytix Biopharma AS - Pipeline Products By Target 19
Lytix Biopharma AS – Pipeline Products by Route of Administration 20
Lytix Biopharma AS – Pipeline Products by Molecule Type 21
Lytix Biopharma AS – Recent Pipeline Updates 22
Lytix Biopharma AS – Operations and Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 25
Contact Us 25
Disclaimer 25

List of Tables
Lytix Biopharma AS – Pipeline by Therapy Area and Indication, 2011 6
Lytix Biopharma AS – Pipeline by Stage of Development, 2011 7
Lytix Biopharma AS – Monotherapy Products in Pipeline, 2011 8
Lytix Biopharma AS – Combination Treatment Modalities in Pipeline, 2011 9
Lytix Biopharma AS - Phase II, 2011 10
Lytix Biopharma AS - Phase I, 2011 11
Lytix Biopharma AS - Pipeline By Therapeutic Class, 2011 18
Lytix Biopharma AS - Pipeline By Target, 2011 19
Lytix Biopharma AS – Pipeline By Route of Administration, 2011 20
Lytix Biopharma AS – Pipeline By Molecule Type, 2011 21
Lytix Biopharma AS – Recent Pipeline Updates, 2011 22
Lytix Biopharma AS, Other Locations 23

List of Figures
Lytix Biopharma AS – Pipeline by Therapy Area and Indication, 2011 6
Lytix Biopharma AS – Pipeline by Stage of Development, 2011 7
Lytix Biopharma AS – Monotherapy Products in Pipeline, 2011 8
Lytix Biopharma AS – Combination Treatment Modalities in Pipeline, 2011 9
Lytix Biopharma AS – Pipeline By Therapeutic Class, 2011 18
Lytix Biopharma AS - Pipeline By Target, 2011 19
Lytix Biopharma AS – Pipeline By Route of Administration, 2011 20
Lytix Biopharma AS – Pipeline By Molecule Type, 2011 21